The nuclear protein prothymosin-a (ProTa), which lacks a signal peptide sequence, is released from neurons and astrocytes on ischemic stress and exerts a unique form of neuroprotection through an anti-necrotic mechanism. Ischemic stress-induced ProTa release is initiated by a nuclear release, followed by extracellular release in a non-vesicular manner, in C6 glioma cells. These processes are caused by ATP loss and elevated Ca 2 þ , respectively. S100A13, a Ca 2 þ -binding protein, was identified to be a major protein co-released with ProTa in an immunoprecipitation assay. The Ca 2 þ -dependent interaction between ProTa and S100A13 was found to require the C-terminal peptide sequences of both proteins. In C6 glioma cells expressing a D88-98 mutant of S100A13, serum deprivation caused the release of S100A13 mutant, but not of ProTa. When cells were administered apoptogenic compounds, ProTa was cleaved by caspase-3 to generate a C-terminal peptide-deficient fragment, which lacks the nuclear localization signal (NLS). However, there was no extracellular release of ProTa. All these results suggest that necrosisinducing stress induces an extacellular release of ProTa in a non-vesicular manner, whereas apoptosis-inducing stress does not, owing to the loss of its interaction with S100A13, a cargo molecule for extracellular release.
Prothymosin-a (ProTa), a nuclear protein, is widely distributed throughout the body and has various intracellular functions in determining life and death. 1, 2 ProTa bearing a conventional nuclear localization signal (NLS) is largely localized in the nucleus, and has important functions in the regulation of cell differentiation and proliferation. [1] [2] [3] When a cell is subjected to apoptotic stimuli, on the other hand, ProTa is released from the nucleus to the cytosol in which it inhibits apoptosome formation. 4 Thus, ProTa is supposed to have a proliferative function in the nucleus under normal conditions, and a selfdefensive function in the cytosol under apoptotic conditions.
We have recently identified ProTa as a unique anti-neuronal necrosis factor in the conditioned medium (CM) of cortical neurons, 5 and discovered its potent neuroprotective functions in cerebral and retinal ischemia. 6, 7 This protein is extracellularly released on starving or ischemic stress, and inhibits necrosis by inducing the membrane translocation of glucose transporters, which are endocytosed under ischemic conditions, resulting in an acceleration of necrosis owing to energy crisis. 5 On the basis of pharmacological analyses, ProTainduced translocation of glucose transporters is mediated by stimulation of a putative G i/o -coupled receptor, phospholipase C, and protein kinase C (PKC) b II . This fact indicates that ProTa has another self-defensive function as an extracellular signal under conditions inducing necrosis.
However, little is known of the mechanisms underlying extracellular ProTa release. Of importance are the facts that the majority of ProTa content in the nucleus is extracellularly released on stress, before membrane disruption, 5 and that ProTa lacks a signal peptide sequence, which is required for sorting to the endoplasmic reticulum (ER)-Golgi system before exocytosis. Therefore, ProTa release seems to proceed in a non-classical or non-vesicular manner under ischemic stress conditions. Here, we report the ischemiainduced nuclear release of ProTa, followed by its interaction with S100A13, a cargo molecule for extracellular release. We also discuss the mechanism underlying the lack of extracellular ProTa release under apoptotic conditions.
Results
Serum-deprivation stress-induced non-classical release of ProTa. ProTa is exclusively localized in the nuclei of various cells, including neurons. [1] [2] [3] Starvation stress caused by serum deprivation induced a disappearance of ProTa from neurons and astrocytes, as early as 3 h after the start of primary culture (Figure 1a) . Recently, we discovered the release of this protein into the CM of cultured cortical neurons under serum-free starving conditions causing necrosis. 5 As shown in Figure 1b , when serum-derivation stress was given to neurons or astrocytes, the amounts of ProTa in both cell types markedly decreased at 3 h. On the other hand, the ProTa levels in the CM of both cell types in the presence of serum were negligible. However, the serum-deprivation stress caused a significant extracellular release of ProTa from both cell types. Brefeldin A, a blocker of protein transport from the ER to the Golgi apparatus, did not affect Figure 1 Serum-deprivation stress induced the brefeldin-A-insensitive non-classical extracellular release of ProTa. (a) Altered distribution of ProTa in cortical neurons and astrocytes. Cells were fixed for immunocytochemistry 3 h after serum-deprivation stress, indicated as serum (À). Arrowheads denote the nuclei of cells showing ProTa release. (b) ProTa release in cortical neurons and astrocytes induced by serum (À) stress. ProTa, a highly acidic protein, was purified from 5 Â 10 5 cells and their CM using a phenol extraction procedure, and visualized with Coomassie brilliant blue. Data represent the means ± S.E.M. of five independent experiments [*P ¼ 0.01, versus the corresponding serum ( þ ) treatment]. (c) Characterization of brefeldin A-insensitive non-classical extracellular release of ProTa. Brefeldin A (BFA; 8 mg/ml) was added to the culture of cortical neurons and astrocytes 12 h before serum deprivation. CM samples (n ¼ 5) were used for the purification of ProTa. (d) Real-time imaging of serumdeprivation stress-induced ProTa release. ProTa-EGFP stably expressed in C6 glioma cells was released on serum-deprivation stress. (e) Serum-deprivation stress-induced ProTa release in a BFA-insensitive manner. CM samples from C6 glioma cells culture were collected at 90 min after serum-deprivation stress (90 min). Scale bars represent 20 mm. Re: recombinant rat ProTa ProTa release (Figure 1c) , suggesting that the manner of release differs from conventional vesicular release. Extracellular release of ProTa was also observed in a rat astroglial C6 glioma cell line after serum deprivation. In C6 glioma cells expressing ProTa-EGFP, the serum-deprivation stress-induced decrease of fluorescence in nuclei started as early as 20 min after serum deprivation, and complete disappearance was observed at 80 min, although a small population of cells (below 5%) still retained fluorescence (Figure 1d ). However, no significant fluorescence signal was observed in the cytosol at these time points, suggesting that stress-induced nuclear export of ProTa is a rate-limiting step in the non-classical extracellular release of ProTa. As seen with primary neurons and astrocytes, brefeldin A did not affect the serum-deprivation stress-induced release of native ProTa release from C6 glioma cells (Figure 1e ).
ATP-dependent nuclear localization of ProTa. We have earlier reported that serum-free starvation stress causes a rapid decrease in cellular ATP levels, leading to necrosis and extracellular ProTa release from the nucleus. 5 As shown in Figure 2a , the addition of 2-deoxy-D-glucose (2-DG) to cultured C6 glioma cells in serum-containing medium caused a rapid decrease in ATP levels. When the subcellular localization of ProTa was examined (Figure 2b ), the addition of 2-DG to cells without serum-starvation stress decreased the number of cells showing nuclear localization of ProTa, and increased the number showing cytosol localization. However, no significant extracellular ProTa release was observed. On the other hand, serumdeprivation treatment decreased the number of cells showing nuclear localization and increased the number showing extracellular release. Thus, these results suggest that the loss of cellular ATP induces the transport of ProTa from the nucleus to cytosol, but is not sufficient to cause extracellular release of ProTa from the cytosol.
We studied the machinery underlying nucleus-to-cytosol export. When Alexa Fluor488-labeled ProTa and Alexa Fluor568-bovine serum albumin (BSA) were co-injected into the cytosols of C6 glioma cells, Alexa Fluor488-ProTa was rapidly localized to the nucleus, within 10 min, whereas Alexa Fluor568-BSA remained in the cytosol (Figure 2c , upper left 4 panels). Treatment of cells with 2-DG abolished the nuclear localization of Alexa Fluor488-ProTa and redistributed it throughout the cell (Figure 2c , upper middle 4 panels). This re-distribution was completely reversed by co-injection of ATP (Figure 2c , upper right 4 panels). On the other hand, serum deprivation caused a re-distribution of ProTa from nucleus to cytosol, but did not result in extracellular release in the presence of amlexanox, which inhibits the release of proteins lacking a signal peptide sequence [8] [9] [10] [11] ( Figure 2c , lower panels). Similarly, co-injection of ATP reversed the nucleusto-cytosol export. Thus, it is evident that nuclear localization of ProTa is closely related to the cellular ATP level.
Importin a has an important function in the nuclear localization of proteins possessing an NLS. For the sustained localization of such proteins, importin a should be released into the cytosol for repeated use. The GTP-bound form of Ran, a small GTP-binding protein, is known to execute this importin recycling process. 12 Therefore, the loss of cellular ATP is expected to impair the nuclear localization of ProTa owing to difficulty maintaining the GTP-bound state of Ran. Indeed, the nuclear localization of ProTa-EGFP was clearly impaired by injection of anti-importin a IgG into C6 glioma cells (Figure 2d ). However, the nuclear levels of ProTa were not affected by leptomycin B, an inhibitor of the nuclear export receptor CRM1 (data not shown). When wheat germ agglutinin, an inhibitor of the nuclear pore complex, was injected into the nuclei of C6 glioma cells, ProTa was redistributed throughout the cells (Figure 2e ). All of these findings suggest that ProTa is localized in the nucleus through an ATP-dependent importin-NLS mechanism, 13 and that nucleus-to-cytosol export owing to loss of ATP occurs through passive diffusion.
Stress-induced extracellular co-release of ProTa with S100A13. When the CM from serum-deprived C6 glioma cells was immunoprecipitated with anti-ProTa IgG, two significant protein bands were stained by CBB (Figure 3a) . The upper band was identified as ProTa by immunoblot using an acidic protein transfer procedure.
14 The lower band, at approximately 10 kDa, was identified by matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) (five peptides, 57.1% coverage) followed by MS/MS sequencetag analysis using the NCBI protein database, as S100A13, a member of the Ca 2 þ -binding S100 family. [15] [16] [17] Immunoblotting also confirmed that this protein is identical to S100A13. As shown in Figure 3b , naturally occurring ProTa is localized within nuclei, whereas S100A13 is evenly distributed throughout cells. When cultured cells were deprived of serum, both ProTa and S100A13 were completely lost from cells at the time point of 3 h. The cellular loss of S100A13 and ProTa was also blocked by amlexanox, a potent inhibitor of S100A13. [8] [9] [10] [11] 18 Quantitative immunoblot analysis confirmed that amlexanox abolished the serum-deprivation stressinduced extracellular release of ProTa (Figure 3c ).
Protein-protein interaction between ProTa and S100A13. The interaction between ProTa and S100A13 was characterized by use of various deletion mutants of both proteins. In this study, GST-tagged ProTa and Strep-tagII-S100A13 were used (Figure 4a ). The addition of Strep-tagII-S100A13 to GST-ProTa immobilized on the sensor tip of a quartz crystal microbalance (QCM) decreased the quartz oscillation, as quantified by the oscillation unit (OU: DF in Hz), which represents the degree of interaction between the two proteins, as reported earlier. 19 The interaction between proteins was enhanced in the presence of Ca 2 þ , but not in the presence of Mg 2 þ or Cu 2 þ , and this enhancement was Ca 2 þ dependent in the range 0.1-200 mM (Table 1; Figure 4b ). As the Ca 2 þ -dependent interaction was further enhanced by the addition of Cu 2 þ (Table 1) , which has substantial binding affinity for S100A13, we used the addition of both Ca 2 þ and Cu 2 þ (100 mM and 100 nM, respectively) to determine the best ionic conditions for the interaction between GST-ProTa and Strep-tagII-S100A13. From the kinetic analysis, 19 the saturated OU max for the interaction of Strep-tagII-S100A13 with immobilized GST-ProTa (430 fmol) was 201.44±3.53 OU, which corresponds to S100A13-dependent non-vesicular release of ProTa H Matsunaga and H Ueda 435.63 ± 7.63 fmol. Therefore, it is evident that ProTa and S100A13 interact at a ratio of 1 : 1. The C-terminal domains of several types of S100 family proteins are reported to interact with various target proteins. 16 Among these proteins, S100A13 has a unique C-terminal 11-amino-acid sequence (RKEKVLAIRKK), which contains as many as six basic amino acids. In the QCM analysis, Strep-tagII-S100A13 lacking this C-terminus (amino-acids Figure 2 Mechanism underlying the nuclear transport of ProTa. (a) Decrease in intracellular ATP levels induced by serum-deprivation stress. Time courses of intracellular ATP levels were measured in ProTa-EGFP stably expressing C6 glioma cells subjected to serum-deprivation stress or treated with 2-DG (10 mM, with serum). (b) Altered distribution of ProTa-EGFP by serum (À) or 2-DG treatments (3 h). Distribution of ProTa-EGFP was measured after fixation of C6 glioma cells and visualization of nuclei with Hoechst 33342. Data represent the means ± S.E.M. of 4-6 independent experiments. (c) ATP-induced recovery of nuclear import of ProTa after 2-DG treatment or serum (À) stress in the presence of amlexanox (100 mM). Alexa Fluor488-ProTa and Alexa Fluor568-BSA, with or without ATP (3 mM in a needle), were co-injected into cytoplasm. (d) Nuclear import of ProTa mediated by importin a. Importin a, a nuclear transport receptor, binds to classical NLS-containing proteins and links them to the nuclear pore complex. Re-distribution of ProTa-EGFP after cytosolic co-injection of anti-importin a IgG (0.1 mg/ml in a needle) and Alexa Fluor568-BSA. (e) Passive diffusion of ProTa as a nuclear export mechanism. Injection of wheat germ agglutinin (WGA, 2.0 mg/ml in a needle) into the nucleus induced a re-distribution of ProTa throughout the cell. Scale bars represent 20 mm 88-98) showed no significant interaction with ProTa ( Figure 4c ). On the other hand, in the experiments using immobilized Strep-tagII-S100A13, the C-terminal deletion mutants ProTa (D79-112) and ProTa (D102-112) showed decreased potency for interaction (association rate constant: k a ), whereas the N-terminal deletion mutants ProTa (D1-68) and ProTa (D1-86) did not ( Figure 4d ). As the C-terminal peptide ProTa (amino-acids 102-112; TKKQKKTDEDD), but not its reverse peptide (DDEDTKKQKKT), inhibited the interaction between GST-ProTa and Strep-tagII-S100A13 (Figure 4e ), the C-terminal sequence appears to have a crucial function in this interaction. On the contrary, the N-terminal region is presumed to have an unidentified regulatory function in this interaction.
Interaction between ProTa and S100A13 is required for the extracellular release of ProTa. To confirm that the stress-induced extracellular release of ProTa depends on the ProTa-S100A13 interaction, we established C6 glioma cells stably expressing Strep-tagII-S100A13 D88-98, which lacks affinity for ProTa. In the immunocytochemical study, serumdeprivation stress caused an extracellular release of both ProTa and Strep-tagII-S100A13 full-length mutant from C6 glioma cells (Figure 5a , left panels, and 5b). However, with the Strep-tagII-S100A13 D88-98 mutant, serum-deprivation stress caused the release of the mutant protein, but not ProTa ( Figure 5a , right panels, and 5b). This finding suggests that the C-terminal basic residue-rich domain of S100A13 is required for the interaction with ProTa in living cells, and that S100A13 has a function as a cargo molecule involved in the extracellular export of ProTa. To identify the intracellular locales of interaction between ProTa and S100A13, we performed Strep-tagII pull-down assay using nuclear and cytosolic fractions from C6 glioma cells stably expressing Strep-tagII-S100A13 (Figure 5c ). In the absence of stress, there was no interaction between Strep-tagII-S100A13 and ProTa in either nuclear or cytosol fraction. Under the serumdeprivation stress, however, a significant interaction was observed in the cytosol fraction, but not in the nuclear one. The level of co-precipitated ProTa in the cytosol was decreased in a time-dependent manner in the range between 1 and 3 h, possibly because of the loss of cytosolic ProTa by extracellular release of both proteins. To evaluate the ProTa-S100A13 interaction in living cells, we performed fluorescence resonance energy transfer (FRET) analysis. However, the representative FRET analysis using a pair of CFP and YFP was not successful, because the YFP-fused ProTa showed an abnormal distribution. Instead, we attempted to assess the interaction between ProTa-EGFP and DsRed2-S100A13 in the presence of amlexanox, which has no direct effect on their interaction (Table 1 ). In addition, we performed using phenol red-free DMEM, which does not decrease the survival activity of C6 glioma cells under serum-deprivation condition (Supplementary Figure  S1 ). In the cell population, FRET analysis in the presence of amlexanox, the serum-deprivation stress-induced interaction between ProTa and S100A13 (Figure 5d ), and ProTa and S100A13 were redistributed throughout the cell (Figure 5g ). To calculate the FRET efficiency, we performed acceptor photo-bleaching. When the acceptor (DsRed2-S100A13) was earlier bleached, serum-deprivation stress did not cause elevation of FRET ratio; however, ProTa and S100A13 were also redistributed throughout the cell (Figure  5d and g ). Next, we performed the single cell FRET analysis in the absence of amlexanox. As shown in Supplementary Figure S2a , the FRET ratio in the cytosol was rapidly increased at 80 min after serum deprivation, whereas then gradually decreased, possibly because of the extracellular release of ProTa-S100A13 complex. In accord with this observation, the fluorescence intensity derived from donor ProTa-EGFP decreased at 80 min, whereas the one derived from acceptor DsRed2-S100A13 transiently increased (Supplementary Figure S2b) . These results strongly suggest that the interaction between ProTa-EGFP and DsRed2-S100A13 occurs in the cytosol. As shown in Figure 5e , the serum-deprivation stress-induced interaction Figure 3 Identification of S100A13 co-released with ProTa on serum-deprivation stress. (a) S100A13 is a major protein interacting with extracellular ProTa. CM from serum-deprived C6 glioma cells (3 h) was subjected to immunoprecipitation with anti-ProTa or pre-immune IgG. Lower band was identified as S100A13 (arrow). Re, recombinant rat ProTa; IB, immunoblot. (b) Blockade of stress-induced extracellular release of ProTa and S100A13 by amlexanox. Cells were subjected to serumdeprivation stress ( S100A13-dependent non-vesicular release of ProTa H Matsunaga and H Ueda Table 1 The association rate constant (k a ) and dissociation constant (K D ) value of Strep-tagII-S100A13 for GST-ProTa in the QCM assay The interaction between ProTa and S100A13 was in a Ca 2+ -dependent manner. The interaction was analyzed by both GST-ProTa and Strep-tagII-S100A13. GSTProTa was immobilized on the anti-GST antibody-coated sensor chip, hence orientation of ProTa (host sample) was fixed. The k a and K D values were obtained by the analysis using cumulative application of Strep-tagII-S100A13 (guest sample). Cu 2+ potentiated the Ca 2+ -dependent interaction between GST-ProTa and Strep-tagII-S100A13. Amlexanox did not affect this interaction. Each experiment was analyzed in interaction buffer. The data shown are mean±S.E.M. of 3-5 independent experiments. *Po0.05 and **Po0.01 versus corresponding control (A and E) 
between ProTa and S100A13 was abolished by the C-terminal (102-112) peptide of ProTa, but not by the reverse peptide. The treatment with C-terminal peptide inhibited the serumdeprivation-induced extracellular release of ProTa, but not S100A13, whereas the reverse peptide did not inhibit the extracellular release of either protein (Figure 5h , upper 6 panels).
S100A13-dependent non-vesicular release of ProTa H Matsunaga and H Ueda
Ca 2 þ influx is involved in the extracellular release of ProTa based on the interaction with S100A13. In the FRET analysis (Figure 5f ), the serum-deprivation stressinduced interaction between ProTa and S100A13 was abolished when the cells were treated with EGTA or BAPTA-AM, extracellular and intracellular Ca 2 þ -chelating agents, respectively. The serum-deprivation-induced loss of these proteins was also abolished by EGTA or BAPTA-AM (Figure 5h, lower 4 panels) .
Caspase-catalyzed cleavage of ProTa inhibits the stressinduced extracellular release. When C6 glioma cell culture was carried out in various concentrations of serum, significant depletion of ProTa was observed in the absence of serum, but not in the presence of 2 or 10% serum (Figure 6a , upper 6 panels, and 6b). When staurosporine, tunicamycin, and etoposide, which are known to induce apoptosis, were added to 2% serum medium, ProTa was redistributed throughout the cell (Figure 6a , middle 6 panels). However, these apoptogenic compounds did not cause any significant extracellular release of ProTa, but led to the production of large amounts of a smaller ProTa fragment (Figure 6b ). These re-distribution and fragmentation of ProTa were in a caspase-3 inhibitor zDEVD-fmk-reversible manner (Figure 6a , lower 6 panels and 6b). On the other hand, these compounds did not affect intracellular ATP levels (Supplementary Figure S3) .
When rat ProTa was treated with active caspase-3, a 13 kDa protein band was time dependently generated in a zDEVD-fmk-reversible manner (Figure 6c ). This finding is consistent with reports that human ProTa has three overlapping caspase-3 cleavage sites, 94DDED97, 95DEDD98, and 97DDVD101, 20, 21 immediately upstream of the NLS moiety in its C-terminus, and that this fragment lacks an NLS moiety KKQK, which is present in rat ProTa at amino-acid positions 103-106. To identify the cleavage sites of rat ProTa by active caspase-3, we performed MALDI-TOF analysis. As shown in Figure 6e , MALDI-TOF analysis revealed that the molecular mass of purified ProTa in naive C6 glioma cells was 12259.99, which corresponds to N-terminal serine acetylated full-length size (Ac2-112), whereas ProTa-like molecule in apoptogenic staurosporine-treated cells was 10480.39 or 10596.43, which corresponds to C-terminal truncated ProTa Ac2-97 or Ac2-98, respectively. Tunicamycin or etoposide treatments also showed similar results (data not shown). Next, we tried to characterize the cleavage region of recombinant rat ProTa (rrProTa) by caspase-3 by use of peptide mass fingerprinting analysis. In this experiment, rrProTa was incubated with or without active rat caspase-3, followed by a separation with SDS-PAGE, in-gel digestion of protein bands with trypsin and MALDI-TOF analysis (Figure 6f ). In the absence of incubation of active rat capase-3 (blue peaks), two peaks with molecular mass of 1131. 15 (Figure 6g ). All these results indicate that rat ProTa has the two over-lapping cleavage sites by caspase-3 ( Figure 6d ). Accordingly, ProTa likely loses its NLS moiety under apoptotic conditions. This view is supported by the finding that immunoreactive ProTa is no longer localized in the nucleus after treatment of cells with apoptogenic compounds (Figure 6a ). On the basis of the finding that the ProTa fragment was not released from cells, this C-terminal region appears to be essential for the extracellular release of ProTa.
Discussion
The nuclear protein ProTa currently attracts the interest of investigators in terms of life and death decisions in various cell types. In the nucleus, this protein epigenetically stimulates cell proliferation by binding to histones, 22 p300 histone acetyltransferase, 23 and CREB-binding protein. 24 ProTa also enhances estrogen receptor transcriptional activity by binding to its repressor, 25 and binds to Keap1 to release Nrf2, which in turn upregulates various kinds of anti-oxidant enzymes important for survival. 26 Under the apoptotic conditions, it inhibits apoptosome formation. 4 Most recently, we discovered this protein as an anti-necrosis factor in the CM of cultured cortical neurons under serum-free starving conditions causing Figure 5 S100A13 is a cargo molecule mediating extracellular ProTa release. (a) S100A13 D88-98 mutant as a dominant-negative regulator of ProTa release. Distributions of ProTa and Strep-tagII-S100A13 mutants in cultured C6 glioma cells with or without serum. (b) Loss of interaction of the Strep-tagII-S100A13 D88-98 mutant with ProTa in living cells. Cells and CM from C6 glioma cells stably expressing Strep-tagII-S100A13 mutants with or without serum (3 h) were harvested and a Strep-tagII pulldown assay was performed. Re: recombinant rat proteins. (c) The interaction of the Strep-tagII-S100A13 with ProTa occurs in cytosol, but not nucleus. Nucleus (N) and cytosol (C) from C6 glioma cells stably expressing Strep-tagII-S100A13 mutants with or without serum (3 h) were prepared and a Strep-tagII pull-down assay was performed. (d-f) Imaging of the ProTa-S100A13 interaction in living cells. Time-course of FRET images after serum-deprivation stress in phenol red-free DMEM. DsRed2-S100A13 was transiently expressed in C6 glioma cells stably expressing ProTa-EGFP. The FRET ratio represents the emission ratio of 590/520 nm. (d) Serum-deprivation stress-induced increase in the FRET emission ratio. Cell population images of FRET were measured in the presence of amlexanox (100 mM). Serum-deprivation stress caused an increase in the emission ratio from approximately 90 min. When the acceptor (DsRed2-S100A13) was earlier bleached, serum-deprivation stress did not increase the emission ratio. In cells expressing EGFP instead of ProTa-EGFP, FRET did not occur after serum deprivation. (e) Inhibition of FRET by the ProTa C-terminal peptide. Cellular delivery of a C-terminal peptide (amino-acids 102-112; forward peptide) of ProTa abolished increase of FRET emission ratio and decreased basal level, whereas no change was observed with the reverse peptide. (f) Inhibition of FRET by Ca 2 þ chelating. Cytosolic and extracellular Ca 2 þ -chelating agents, BAPTA-AM, and EGTA, respectively, inhibited FRET after serum deprivation. A decrease in the basal level of the emission ratio was observed approximately 70 min after the stress, suggesting that nuclear ProTa-EGFP is redistributed into the cytosol, but does not interact with S100A13 in the absence of Ca 2 þ . BAPTA-AM and EGTA were used at 1 mM and 1 mM, respectively. (g) Subcellular distribution of ProTa-EGFP and DsRed2-S100A13. The images were collected 180 min after serum deprivation after FRET analysis. (h) Inhibition of extracellular release of ProTa-EGFP and DsRed2-S100A13. The images were collected 180 min after serum-deprivation stress. Scale bars represent 20 mm S100A13-dependent non-vesicular release of ProTa H Matsunaga and H Ueda necrosis. 5 Extracellular ProTa completely inhibits neuronal necrosis, but causes apoptosis in a different manner in cultured neurons. [27] [28] [29] However, after stroke, endogenous neurotrophins, such as brain-derived neurotrophic factor (BDNF) or erythropoietin, have been found to inhibit the apoptosis induced by exogenously administered ProTa. 6 In Figure 6 Apoptotic stress induces re-distribution of ProTa. (a) Altered distribution of ProTa in C6 glioma cells. Cells were subjected to serum-reduced (2%) or serumdeprivation stress for 3 h. Cells were treated with staurosporine, tunicamycin, or etoposide for 3 h in the presence or absence of zDEVD-fmk (10 mM). All apoptogenic compounds were used at 1 mM in 2% serum-containing medium. Scale bars represent 20 mm. the retinal ischemia model, the ischemic stress depletes ProTa from the retinal cells, and the intravitreous pretreatments with anti-ProTa IgG or antisense oligodeoxynucleotide against ProTa deteriorated the ischemic damage. 7 Therefore, it is evident that ProTa is extracellularly released from nuclei on ischemic stress, and that it exerts endogenous neuroprotective functions.
Polypeptide secretion has largely been defined as a process of exocytosis through the fusion of vesicles containing bioactive substances to the plasma membrane. In the representative vesicular secretion pathway, polypeptides that possess a signal peptide sequence in their N-terminal region are sorted to the ER-Golgi system to be processed by exocytosis. 30, 31 However, several polypeptides possess extracellular functions despite lacking a signal sequence. The extracellular release of such polypeptides has to proceed through ER-Golgi-independent or non-vesicular (so-called non-classical) routes. It should be noted that these polypeptides showing non-classical extracellular release in general have significant functions in the life and death decisions of cells, as seen in the cases with angiogenic growth factors, inflammatory cytokines, extracellular matrix growth factors, viral proteins, and parasite surface proteins. 32, 33 Unlike vesicular release, this type of release is caused by non-physiological stressful stimuli, which may cause rapid cell death. A series of pioneering studies by Maciag and his coworkers led to the hypothesis that S100A13 has key functions in the so-called non-classical extracellular release.
8 S100A13 has two EF-hand Ca 2 þ -binding motifs and belongs to a member of the S100 family. [15] [16] [17] It has been reported that S100A13 is involved in the non-classical extracellular release of target molecules containing fibroblast growth factor-1 (FGF-1) and interleukin-1a. [9] [10] [11] 19, 34, 35 In this study, we successfully showed that ProTa is another example of stress-induced non-vesicular extracellular release, using S100A13, a cargo molecule. Furthermore, we revealed that the C-terminal regions of ProTa and S100A13 are essential for their interaction, which precedes extracellular release of both proteins, and that caspase-3 cleaves off C-terminal regions of ProTa. Thus, the non-vesicular extracellular release of ProTa has a unique feature that it is does not occur under the condition of apoptosis.
The unique point in this study is observed in the fact that ProTa is strictly localized in the nucleus in neurons, astrocytes, and C6 glioma cells. The mechanism underlying ischemic stress-induced extracellular release of ProTa comprises a two-tier export system: from the nucleus to the cytosol, and from the cytosol to outside the cell. As mentioned above, the nuclear export of ProTa is attributed to ischemiainduced ATP loss, which impairs the importin-NLS mechanism. As this nuclear export was not affected by leptomycin B, the serum-deprivation stress-induced drastic decrease in nuclear levels of ProTa is likely to be due to passive diffusion. Interestingly, once ProTa is exported from the nucleus, it is disappeared without remaining in the cytosol. In other words, nuclear export is the rate-limiting step for non-vesicular and extracellular release of ProTa.
The stress-induced extracellular release of ProTa was impaired by the addition of cytosolic or extracellular Ca 2 þ -chelating agents. The interaction between ProTa and S100A13 was Ca 2 þ concentration dependent in the range 0.1-200 mM, which corresponds to the cellular levels between resting and stimulated conditions. The Ca 2 þ dependency seems to be attributed to the facts that both S100A13 and ProTa are Ca 2 þ -binding proteins. [15] [16] [17] 36 On the basis of the observation that serum-deprivation stress causes the activation of voltage-dependent N-type Ca 2 þ channel, which is involved in the non-classical release of FGF-1 and S100A13, 34, 35 ischemic stress-induced Ca 2 þ influx may underlie the non-vesicular ProTa release as the second step after ATP loss-dependent nuclear release.
Neurons die by necrosis in the low density of culture under the serum-starved condition, but their survival activity increases as the cell density goes. We identified ProTa as the important molecule, which is released in the CM of serumstarved culture of neurons, and suppresses the necrosis through a recovery of glucose transport and ATP supply. 5, 37 After longer culture with ProTa, however, we found that neurons die by apoptosis through activation of caspase-3.
5 As caspase-3 is known to cleave poly-[ADP-ribose] polymerase, which consumes abundant ATP molecule for the restoration from stress-induced damage of DNA, 38 this machinery seems to have some functions in suppression of rapid necrosis by stress. 29 As the concomitant addition of anti-apoptotic neurotrphins with ProTa completely inhibits the cell death, the physiological meaning of ProTa action would be speculated as a conversion of uncontrollable cell death necrosis to controllable apoptosis. Indeed, this speculation was confirmed by in vivo study, in which exogenous ProTa inhibited both necrosis and apoptosis of retinal cells after ischemia, but the further treatment with anti-BDNF antibody disclosed the apoptosis induction by ProTa. 7 It should be noted that ProTa in the cytosol inhibits apoptosis through an inhibition of apoptosome formation in non-neuronal HeLa cells. 4 Furthermore, there is a report that ProTa is released from the nuclei when the NLS is cleaved off by caspase-3. 20, 21 This study clearly showed that the C-terminal region of ProTa including NLS is cleaved in culture by the apoptosis-induced compound, and in cell-free digestion of recombinant ProTa by active caspase-3 (Figure 6d-g ). As ProTa devoid of C-terminal region (a.a.98 or 99-112) is conceived to lose the activity of interaction with S100A13 (Figure 4d ), it will remain in the cytosol without extracellular release. All these findings enable us to speculate that ProTa extracellularly released on the necrosis condition inhibits neuronal necrosis in an autocrine or paracrine manner, whereas cytosolic ProTa redistributed from the nuclei on the apoptotic condition may have an anti-apoptotic self-defensive function.
It is well known that several endogenous molecules are released in response to injury, infection, or other inflammatory stimuli, and initiate inflammatory responses. These molecules are so-called damage-associated molecular patterns (DAMPs) and/or alarmins. 39, 40 Although DAMPs have intranuclear and/or intracellular functions under normal conditions, they have extracellular effects under pathological conditions. High-mobility group box1 (HMGB1), a representative DAMP molecule, has similar characteristics to ProTa. HMGB1, a nuclear protein, is released by necrotic stress, but not by apoptosis, as seen for ProTa. However, it causes S100A13-dependent non-vesicular release of ProTa H Matsunaga and H Ueda cell damaging or inflammatory actions. Although this release is reported to occur through passive diffusion through necrosis-induced membrane disruption, detailed characterization of the mechanism is required. It is interesting to propose that ProTa is a novel type of DAMP bearing celldefensive functions in brain.
In conclusion, we showed that the nuclear protein ProTa is extracellularly released from neurons, astrocytes, and C6 glioma cells on ischemic stress in a non-vesicular manner. The initial step of this release is nuclear release of ProTa owing to the stress-induced ATP loss. Non-vesicular extracellular release of ProTa is dependent on a Ca 2 þ -sensitive interaction with S100A13. We also showed that ProTa loses the ability to undergo extracellular release under apoptotic conditions, owing to loss of its interaction with S100A13, a cargo molecule. Expression constructs and purification procedures for proteins. The rat ProTa gene was amplified from cDNA derived from rat embryonic brain. The PCR primers used were ProTa-F, 5
0 -AACATATGTCA GACGCGGCAGTGGA-3 0 (containing a NdeI site), and ProTa-R, 5 0 -AAGGATC CAGTGGAGGGTGAATAGGTCAC-3 0 (containing a BamHI site). Recombinant ProTa protein was constructed by cloning the amplified ProTa gene in-frame into the NdeI-BamHI sites of pET-20b (Novagen, San Diego, CA, USA). Native and recombinant ProTa were purified using a phenol extraction procedure 41 and visualized with Coomassie Brilliant Blue (Gelcode blue stain reagent: PIERCE Biotechnology, Rockford, IL, USA). Recombinant GST-ProTa deletion mutants were constructed by cloning the amplified genes blunted at their 5 0 -ends and cloned in-frame into the BamHI (blunted)-EcoRI sites of pGEX-5X-1 (GE Healthcare Bio-Science Corp., Piscataway, NJ, USA). The PCR primers used were as follows:
0 ; D79-112-R, 5 0 -TTGAATTCCTAATCTCCATCTTCTTCCTC-3 0 ; and D102-112-R, 5 0 -TTGAATTCCTACTCAACATCATCATCCTCATC-3 0 . All F-primers contain a BamHI site, whereas all R-primers contain a stop codon and an EcoRI site. The recombinant proteins were purified using Glutathione-Sepharose (GE Healthcare Bio-Science Corp.). An EGFP-ProTa fusion protein, for mammalian expression, was constructed by cloning the amplified genes in-frame into the SacISalI sites of pEGFP-N3 (BD Bioscience Clontech, Palo Alto, CA, USA). The PCR primers used were ProTa-F2, 5 0 -AAGAGCTCATGTCAGACGCGGCAGTGGA-3 0 (containing a SacI site), and ProTa-R2, 5 0 -AAGTCGACGTCATCCTCATCAG TCTTCT-3 0 (containing a SalI site). Plasmid construction and purification procedure of recombinant Strep-tagII-S100A13 protein (full length and D88-98) were performed as described earlier.
34 DsRed2-S100A13 fusion protein, for mammalian expression, was constructed by cloning. The rat S100A13 gene was amplified from cDNA derived from rat embryonic brain. The PCR primers used were S100A13-F, 5
0 -AAGAATTCATGGCAGCAGAGCCCCCGAC-3 0 , and S100A13-R, 5 0 -AAAAGCTTTTACTTCTTGCGAATCGCCAGG-3 0 . The amplified S100A13 gene was cloned into pGEM-T Easy (Promega, Tokyo, Japan), and sub-cloned in-frame into the NotI-SpeI sites of pBluescript SK (Stratagene, La Jolla, CA, USA). Finally, the S100A13 gene was sub-cloned in-frame into the SacI-BamHI sites of pDsRed2-C1 (BD Bioscience Clontech). After cloning, each construct was verified by sequencing. The Escherichia coli strains DH10B and BL21 (DE3) were transformed with each of these constructs for sub-cloning and protein expression, respectively. For the analysis of protein-protein interactions and their modulation by ions, we adopted the following molecular weight values (average mass) for fulllength GST-ProTa and Strep-tagII-S100A13, Ca, and Cu: 39 016.19, 13 840.08, 40.078, and 63.546, respectively.
Cell culture, gene transfection, and peptide delivery. Primary cultures of neurons and astrocytes from 17-day-old embryonic rat brain, and cultures of C6 glioma cells, were prepared as described earlier. 34, 42 Gene constructs were transfected with the NeuroPORTER reagent (Gene Therapy Systems, Inc., San Diego, CA, USA). C6 glioma cells stably expressing recombinant protein were selected and maintained in 1 mg/ml G418. Recombinant protein expression was confirmed in isolated clones by microscopy and by immunoblotting. Synthetic peptides were delivered into living cells using the BioPORTER protein delivery reagent (Gene Therapy Systems, Inc.).
Immunocytochemistry. Cells were fixed in 4% paraformaldehyde in PBS for 30 min and then permeabilized with methanol for 10 min at room temperature. The fixed cells were washed with PBS, incubated in blocking buffer (1% BSA and 0.1% Triton X-100 in PBS) for 3 h at 41C, and then incubated in primary antibody (1 : 300 dilution in blocking buffer) overnight at 41C. Next, the cells were incubated in a secondary antibody conjugated to FITC or Cy3 (Chemicon International Inc., Temecula, CA, USA), and then with rhodamine-conjugated streptavidin (Chemicon International Inc.), each diluted 1 : 500 in blocking buffer. The nuclei were visualized with Hoechst 33342 or propidium iodide (Molecular Probes, Eugene, OR, USA). Images were collected using a BZ-8000 microscope (KEYENCE, Osaka, Japan) with a Â 20 Plan APO lens (Nikon, Tokyo, Japan) or using an LSM 510 META confocal laser microscope with a Â 40 Plan-Neofluar lens or a Â 63 PlanApochromat lens (Carl Zeiss, Oberkochen, Germany).
Gravimetric measurements with a biosensor QCM. Protein-protein interactions were detected using an AffinixQ system (Initium Inc., Tokyo, Japan), a QCM sensor device. Detailed procedures have been described earlier. 19 AT-cut quartz crystals coated with a thin gold surface layer with a fundamental frequency of 27 MHz were used. Immediately before use, the gold surface of the quartz resonator was cleaned with piranha solution (H 2 SO 4 : 30% H 2 O 2 ¼ 3 : 1) for 5 min, and thoroughly washed with double-distilled water. An anti-GST antibody (GE Healthcare Bio-Sciences Corp.) or a streptavidin-conjugated antibody solution (ICN/Cappel Inc.) was applied to the resonator for 30 min to obtain a layer for immobilization of GST-ProTa or Strep-tagII-S100A13, respectively. Next, the resonator was rinsed with interaction buffer (50 mM Tris-HCl pH 7.6, 15 mM NaCl, 140 mM KCl), immersed in interaction buffer (8 ml), and then subjected to immobilization of GST-ProTa or Strep-tagII-S100A13 for 30 min before being placed in fresh interaction buffer. The protein-protein interactions were determined from the frequency changes (OU: DF in Hz) owing to changes in the mass on the electrode at the sub-nanogram level, on application of a small volume (1-10 ml) of protein solution. On the basis of the Sauerbrey formula, an increase of 1 Hz OU is calculated as an interaction of 30.38 pg of a molecule with the biosensor. In all immobilizations of GST-ProTa on the resonator, it was confirmed that approximately 430 fmol of GST-ProTa was immobilized as an absolute amount (an increase of OU: 550 Hz). All experiments were carried out at 25 ± 1 1C. All sensorgram data show the OU value after the association phase. For kinetic analysis, frequency changes induced by cumulatively applied protein were curve fitted to the formula DF ¼ A(e (À1/t)T À1), and the 1/t value was plotted for each concentration of Co-immunoprecipitation analysis and Strep-tagII pull-down assay. For the determination of protein release, cell lysis buffer (150 mM NaCl, 1 mM CaCl 2 , 50 mM Tris-HCl pH 7.8, 1% Triton X-100, and protease inhibitor cocktail) was added to cells (0.5-2 Â 10 6 cells) to a final volume of 1 ml and the samples were sonicated. Cells and CM (1 ml) samples were used after the removal
